Apogee Therapeutics, Inc (NASDAQ:APGE) Projects Accelerated Clinical-Driven Upside After Positive 52-Week APEX Data
Recent Phase 2 maintenance data and renewed institutional buying create a near-term technical momentum backdrop alongside stretched valuation metrics. The balance between clinical catalysts and valuation pressure will dictate directional range trading over the coming weeks.









